Rituximab for chronic lymphocytic leukemia
Author:
Publisher
Informa Healthcare
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
http://www.tandfonline.com/doi/pdf/10.1517/14712598.2012.665444
Reference89 articles.
1. Rituximab
2. The Biology of CD20 and Its Potential as a Target for mAb Therapy
3. CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
4. Store-operated Cation Entry Mediated by CD20 in Membrane Rafts
5. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?;Journal of Autoimmunity;2017-12
2. Endometriosis and Ovarian Cancer: From Molecular Evidences to Clinical Implications;Journal of Endometriosis and Pelvic Pain Disorders;2016-07
3. Potential breakthroughs with investigational drugs for hairy cell leukemia;Expert Opinion on Investigational Drugs;2015-09-02
4. Emerging immunological drugs for chronic lymphocytic leukemia;Expert Opinion on Emerging Drugs;2015-07-03
5. The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma;Expert Opinion on Drug Discovery;2015-06-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3